Cover Image
Market Research Report

Therapeutic Antibody 4-Reports Bundle: Antibody-Drug Conjugates (ADCs), Bispecifics, Biosimilars & Biosuperiors (Four Reports released in 2016)

Published by La Merie Publishing Product code 359751
Published Content info
Delivery time: 1-2 business days
Price
Back to Top
Therapeutic Antibody 4-Reports Bundle: Antibody-Drug Conjugates (ADCs), Bispecifics, Biosimilars & Biosuperiors (Four Reports released in 2016)
Published: June 9, 2016 Content info:
Description

A bundle of four reports in pdf format released in 2016 with a 50% discount for all license types

  • Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis
  • T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals
  • Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
  • Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
Table of Contents
Product Code: LMFR0019

Table of Contents

Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis

0 Abbreviations

1 Executive Summary

2 ADC Pipeline Analysis

  • 2.1 Overview
  • 2.2 Next-to-market ADCs
  • 2.3 Next-to-market Immunoconjugates
  • 2.4 ADCs in Early Clinical Development
  • 2.5 ADCs in IND-Enabling Studies
  • 2.6 ADCs in Preclinical R&D
  • 2.7 Competition among ADCs for the Same Target
  • 2.8 Discontinued ADCs and Clinical Attrition Rate

3 ADC Technology Analysis

  • 3.1 Overview
  • 3.2 Conventional and Emerging ADC Technologies
  • 3.3 Probodies and Novel Preclinical Stage Carriers
  • 3.4 Carrier Systems
  • 3.5 Site-Specific Conjugation Technologies with Antibody Engineering
  • 3.6 Site-Specific Conjugation Technologies without Antibody Engineering

4 ADC Stakeholder Analysis

  • 4.1 Major Pharma and Biotech Companies
  • 4.2 Small and Medium Biopharmaceutical Companies
  • 4.3 ADC Technology and Pipeline Companies
  • 4.4 Companies with Novel Payload Technologies
  • 4.5 Companies with Linker, Conjugation & Carrier Technologies
  • 4.6 Companies with Alternative Targeting Moieties

5 ADC Business Analysis

  • 5.1 Overview of Commercial Opportunities and Perspectives with ADCs
  • 5.2 Commercialization of Approved ADCs
  • 5.3 Fund-Raising
  • 5.4 Mergers and Acquisitions
  • 5.5 Pharma - Biotech Collaboration & Licensing Deals
  • 5.6 Biotech - Biotech Collaboration & Licensing Deals

6 ADC Drug Profiles

  • 6.1 Clinical Stage ADC Drug Profiles
  • 6.2 Pre-IND and Preclinical Stage ADC Drug Profiles
  • 6.3 Immunoconjugate Drug Profiles
  • 6.4 Discontinued ADC Drug Profiles

7 ADC Company Profiles

  • 7.1 Major Pharma and Biotech Companies
  • 7.2 Small and Medium Biopharmaceutical Companies
  • 7.3 ADC Technology & Pipeline Companies
  • 7.4 ADC Payload Companies
  • 7.5 ADC Linker, Carrier & Conjugation Technology Companies
  • 7.6 Companies with Alternative Targeting Moieties

8 References

9 ADDENDUM

10 Tables

T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

1 Introduction

2 Executive Summary

3 Competitive Landscape Analysis

  • 3.1 Stakeholders
    • 3.1.1 Major biopharmaceutical companies
    • 3.2.2 Small & medium pharmaceutical & biotechology companies
  • 3.2 Technologies
  • 3.3 Pipeline
    • 3.3.1 Overview
    • 3.3.2 Targets
    • 3.3.3 Competition with other Treatment Modalities
    • 3.3.4 Administration Regimens of T-cell Redirecting Bispecific Antibodies
    • 3.3.5 Next Wave of T-cell and NK-Cell Redirecting Antibodies
    • 3.3.6 Clincial Experience with T-cell and NK-cell redirecting Bispecific Antibodies
  • 3.4 Commercial value of targets, drugs & technologies
    • 3.4.1 Drug prices and sales
    • 3.4.2 Economic terms of collaboration and licensing agreements
    • 3.4.3 Acquisition price (cost) of companies
    • 3.4.4 Public and private financing rounds

4. Company Profiles

  • 4.1 Major Pharma & Biotech
    • 4.1.1 Amgen
    • 4.1.2 AstraZeneca
    • 4.1.3 Bayer
    • 4.1.4 Boehringer Ingelheim
    • 4.1.5 Eli Lilly
    • 4.1.6 GlaxoSmithKline
    • 4.1.7 Janssen Biotech
    • 4.1.8 Pfizer
    • 4.1.9 Roche
    • 4.1.10 Servier
  • 4.2 Small & Medium Pharma & Biotech
    • 4.2.1 Adimab
    • 4.2.2 Affimed Therapeutics
    • 4.2.3 Alligator Biosciences
    • 4.2.4 Ambrx
    • 4.2.5 CytomX
    • 4.2.6 Emergent BioSolutions
    • 4.2.7 EngMab
    • 4.2.8 Eureka Therapeutics
    • 4.2.9 GEMoaB
    • 4.2.10 Generon
    • 4.2.11 Genmab
    • 4.2.12 Glenmark Pharmaceuticals
    • 4.2.13 Immunocore
    • 4.2.14 MacroGenics
    • 4.2.15 Merus
    • 4.2.16 Molecular Partners
    • 4.2.17 Morphosys
    • 4.2.18 Neovii Biotech
    • 4.2.19 OMT Therapeutics
    • 4.2.20 Pieris
    • 4.2.21 Regeneron Pharmaceuticals
    • 4.2.22 Wuhan YZY Biopharma
    • 4.2.23 Xencor
    • 4.2.24 Zymeworks

5 Technology Profiles

  • 5.1 ADAPTIR
  • 5.2 ART-Ig
  • 5.3 Azymetric Scaffold
  • 5.4 BEAT
  • 5.5 Biclonics
  • 5.6 BiTE
  • 5.7 CrossMab
  • 5.8 DART
  • 5.9 Fc-DART
  • 5.10 Dock-and-Lock (DNL)
  • 5.11 DuoBody
  • 5.12 FynomAbs
  • 5.13 ImmTAC
  • 5.14 Knobs-into-Holes
  • 5.15 mAbXcite
  • 5.16 Modified VelocImmune
  • 5.17 TandAb
  • 5.18 T-Cell Engaging Bi-specific (TCB) Probody
  • 5.19 Triomab
  • 5.20 UniDab
  • 5.21 UniTARG / UniMAB
  • 5.22 XmAb Bispecific
  • 5.23 Y-Body Bispecific

6 Drug & Drug Candidate Profiles

  • 6.1 A-337
  • 6.2 AFM11
  • 6.3 AFM13
  • 6.4 AFM21
  • 6.5 AFM22
  • 6.6 AFM24
  • 6.7 AMG 221
  • 6.8 AMG 330
  • 6.9 AMV-564
  • 6.10 BI 836909
  • 6.11 Bispecific anti-CD3-folate
  • 6.12 Blincyto
  • 6.13 CD79b-TDB
  • 6.14 COVA420
  • 6.15 DR5xCD3 DART
  • 6.16 EM801
  • 6.17 EphA2xCD3 DART
  • 6.18 ERY974
  • 6.19 ES414
  • 6.20 ES425
  • 6.21 GBR1302
  • 6.22 GBR1342
  • 6.23 Her2-TDB
  • 6.24 IL13Rα DART
  • 6.25 IMCgp100
  • 6.26 JNJ-63709178
  • 6.27 JNJ-64052781
  • 6.28 M-706
  • 6.29 M-802
  • 6.30 MCLA-117
  • 6.31 MGD006
  • 6.32 MGD007
  • 6.33 MGD009
  • 6.34 MGD014
  • 6.35 Pasotuxizumab
  • 6.36 PF-06671008
  • 6.37 PRS-343
  • 6.38 PSMA-CD3
  • 6.39 REGN1979
  • 6.40 Removab
  • 6.41 RG7802
  • 6.42 RG7828
  • 6.43 ROR1xCD3 DART
  • 6.44 XmAb13551
  • 6.45 XmAb13676
  • 6.46 XmAb14045
  • 6.47 ZW38

7 References

8 Attachment

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update

A) 2015 Sales of Therapeutic Antibodies

  • Overview: 2015 Biologics Sales per Class of Products
  • Overview: 2015 Therapeutic Antibody Sales per Class of Products
  • Blockbuster Therapeutic Antibodies in 2015
  • Anti-TNF Antibody Sales in 2015
  • Cancer Antibody Sales in 2015
  • Other Anti-Inflammatory Antibody Sales in 2015
  • Ophthalmic Antibody Sales in 2015
  • Cardiometabolic & Anti-Infective Antibody Sales in 2015

B) Biosimilar and Biosuperior Anti-TNF Antibodies - 2016 Update

  • 1. Originator Anti-TNF Antibodies
  • 2. Biosuperior Anti-TNF Antibodies
  • 3. Biosimimilar Anti-TNF Antibodies

C) Biosimilar and Biosuperior Anti-VEGF/-R Antibodies - 2016 Update

  • 1. Marketed Anti-VEGF/R Products in Oncology
  • 2. Anti-VEGF Biosuperiors of Avastin and Zaltrap
  • 3. Anti-VEGF-R Biosuperiors of Cyramza
  • 4. Avastin & Cyramza Biosimilar Pipeline in Oncology
  • 5. Marketed Anti-VEGF Products in Ophthalmology
  • 6. Anti-VEGF Biosuperiors of Lucentis and Eylea
  • 7. Other Anti-VEGF Molecules in Ophthalmology
  • 8. Lucentis Biosimilars in Ophthalmology
  • 9. Eylea Biosimilars in Ophthalmology
  • 10. Off-Label Use of Anti-VEGF in Ophthalmology

D) Biosimilar and Biosuperior Anti-Her2 Antibodies - 2016 Update

  • 1. 2015 Anti-Her2 Antibody Sales
  • 2. Originator Anti-Her2 Antibodies
  • 3. Biosuperior Anti-Her2 Antibodies
  • 4. Biosimilar Anti-Her2 Antibodies
  • 5. Perjeta Biosimilar Antibodies

E) Biosimilar and Biosuperior Anti-CD20 Antibodies - 2016 Update

  • 1. 2015 Sales of Anti-CD20 Antibodies
  • 2. Originator Anti-CD20 Antibodies
  • 3. Biosuperior Anti-CD20 Antibodies
  • 4. Biosimilar Anti-CD20 Antibodies
  • 5. Arzerra Biosimilar Antibodies

F) Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

  • 1. Sales of Anti-EGF-R Antibodies
  • 2. Originator Anti-EGF-R Antibodies
  • 3. Biosuperior Anti-EGF-R Antibodies
  • 4. Biosimilar Anti-EGF-R Antibodies

G) Next Wave of Biosimilar Antibodies - 2016 Update

  • Abatacept Biosimilar Antibodies
  • Aletuzumab Biosimilar Antibodies
  • Denosumab Biosimilar Antibodies
  • Eculizumab Biosimilar Antibodies
  • Omalizumab Biosimilar Antibodies
  • Palivizumab Biosimilar Antibodies
  • Tocilizumab Biosimilar Antibodies
  • Ustekinumab Biosimilar Antibodies
  • Biosimilars of Immune Checkpoint Inhibitor Antibodies

H) Corporate Biosimilar & Biosuperior Therapeutic Antibody Pipelines

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

1. Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

  • T-Cell Redirecting Bispecific Cancer Antibodies
  • NK Cell Redirecting Bispecific Cancer Antibodies
  • Bispecific Immuno-Oncology Antibodies
  • Bispecific Tumor Antigens Targeted Cancer Antibodies
  • Bispecific Antibodies for Inflammatory & Autoimmune Diseases
  • Bispecific Antibodies Outside Oncology & Inflammation
  • Antibody Cocktails & Oligo- and Polyclonal Antibodies

2. Corporate Bispecific Antibody Pipelines

Back to Top